PROLONGED COVID-19 INFECTION IN A CHILD WITH LYMPHOBLASTIC NON HODGKIN
LYMPHOMA: WHICH IS THE BEST MANAGEMENT?
During SARS-CoV-2 pandemic, oncologists manage patients at higher risk
of having a severe course of this infection. This raises new questions
about their correct management, as well as the difficulty of
distinguishing tumor/treatments complications from those related to
Coronavirus disease 2019 (COVID-19). We report a case of an 11 year-old
boy undergoing treatment for T cell lymphoblastic lymphoma who
experienced a prolonged SARS-CoV-2 infection. Oncological therapy was
continued without significant changes compared to the initially planned
treatment. No relevant complications occurred. COVID-19 convalescent
plasma (CP) was administered, resulting in a positive antibody titer
after 24 days.